- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00099723
The Effect of a Probiotic on Hepatic Steatosis
February 10, 2010 updated by: VSL Pharmaceuticals
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver.
It is the most common cause of chronic liver disease in the United States.
The exact cause of NAFLD is unknown, but it is more common among people with conditions such as adult-onset diabetes.
NAFLD can strike people of all ages but most often affects adults between the ages of 40 and 60.
Research indicates that overgrowth of gut bacteria can start a chain of biological processes that stress the liver, causing liver inflammation.
Probiotics, living bacteria taken orally, may decrease the stress on the liver by reducing this bacterial overgrowth and/or strengthening the gut walls.
Because probiotics are generally safe, inexpensive, and easy to tolerate they are an attractive treatment option for NAFLD.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
43 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult-onset diabetes
- Liver biopsy in the previous 2 months with diagnosis of fatty liver and fibrosis stage F2-F3
Exclusion Criteria:
- There are multiple exclusion criteria.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
MRI
|
Liver biopsy
|
Blood work
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Steve Solga, MD, Johns Hopkins University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Study Completion (Anticipated)
December 1, 2005
Study Registration Dates
First Submitted
December 17, 2004
First Submitted That Met QC Criteria
December 17, 2004
First Posted (Estimate)
December 20, 2004
Study Record Updates
Last Update Posted (Estimate)
February 11, 2010
Last Update Submitted That Met QC Criteria
February 10, 2010
Last Verified
December 1, 2004
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SS01305-01
- R21AT001305-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatty Liver
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Hoffmann-La RocheCompletedFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLDGermany, Austria
-
GenfitTerminatedNon-Alcoholic Fatty LiverNetherlands
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
-
University of L'AquilaRecruitingNAFLD- Non Alcoholic Fatty Liver DiseaseItaly
Clinical Trials on VSL#3
-
Dayton Children's HospitalNational Institutes of Health (NIH)TerminatedIrritable Bowel SyndromeUnited States
-
Policlinico HospitalUnknown
-
University of Maryland, BaltimoreNational Center for Complementary and Integrative Health (NCCIH)Terminated
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Recruiting
-
Bambino Gesù Hospital and Research InstituteCompleted
-
Policlinico HospitalCompleted
-
Beth Israel Deaconess Medical CenterTerminated
-
Federico II UniversityUnknown
-
Kaplan-Harzfeld Medical CenterCompletedConstipation | Diarrhea
-
Elena Pita CalandreFerring Pharmaceuticals; Actial Farmaceutica S.r.l.CompletedFibromyalgia | Gastrointestinal DiseaseSpain